Charles River Laboratories International, Inc. (CRL)Healthcare | Diagnostics & Research | Wilmington, United States | NYSE
229.75 USD
-3.66
(-1.568%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:24 a.m. EDT
The stock has exploded upward, gaining nearly 30% in just two weeks, which creates a powerful short-term momentum signal. However, this surge is occurring against a backdrop of deteriorating fundamentals, including negative earnings and a negative return on equity. The recent price action appears to be a reaction to earnings news rather than a fundamental turnaround, especially since the latest annual return was down 24%. While the technicals are screaming buy, the underlying business metrics—specifically the negative profit margins and high debt load—suggest caution for a long-term hold. Options traders are clearly hedging against a reversal, betting that the rally cannot sustain itself without better earnings confirmation. For now, the momentum is strong enough to justify a tactical entry, but the structural weaknesses limit the investment thesis beyond the immediate term. |
| Model | MAE |
|---|---|
| MSTL_126 ✓ | 0.083423 |
| MSTL_52_126 | 0.084026 |
| MSTL_52 | 0.089184 |
| MSTL | 0.089202 |
| AutoARIMA | 0.089471 |
| AutoETS | 0.089490 |
| AutoTheta | 0.095471 |
Forecast horizon: 60 days | Selected: MSTL_126
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 2.74 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.528 |
| Excess Kurtosis | -0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 102.551 |
| Revenue per Share | 81.963 |
| Market Cap | 11,066,535,936 |
| Forward P/E | 18.63 |
| Beta | 1.40 |
| Profit Margins | -4.58% |
| Website | https://www.criver.com |
As of July 11, 2026, 4:24 a.m. EDT: Speculators are heavily positioning for downside protection with near-total open interest in out-of-the-money puts across multiple expiration dates, particularly in December. While ATM call interest remains anchored, the overwhelming put volume suggests a significant fear of a sharp correction or earnings miss, contrasting with the recent price rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4878254 |
| Address1 | 251 Ballardvale Street |
| All Time High | 460.21 |
| All Time Low | 17.1875 |
| Ask | 0.0 |
| Ask Size | 200 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 869,970 |
| Average Daily Volume3 Month | 878,886 |
| Average Volume | 878,886 |
| Average Volume10Days | 869,970 |
| Beta | 1.399 |
| Bid | 230.25 |
| Bid Size | 100 |
| Board Risk | 1 |
| Book Value | 61.05 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 229.75 |
| Current Ratio | 1.361 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 235.81 |
| Day Low | 224.57 |
| Debt To Equity | 102.551 |
| Display Name | Charles River Laboratories |
| Earnings Call Timestamp End | 1,778,157,000 |
| Earnings Call Timestamp Start | 1,778,157,000 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | 889,624,000 |
| Ebitda Margins | 0.22091 |
| Enterprise To Ebitda | 15.722 |
| Enterprise To Revenue | 3.473 |
| Enterprise Value | 13,986,957,312 |
| Eps Current Year | 11.10401 |
| Eps Forward | 12.32956 |
| Eps Trailing Twelve Months | -3.65 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 187.5316 |
| Fifty Day Average Change | 42.2184 |
| Fifty Day Average Change Percent | 0.22512685 |
| Fifty Two Week Change Percent | 48.78254 |
| Fifty Two Week High | 237.86 |
| Fifty Two Week High Change | -8.110001 |
| Fifty Two Week High Change Percent | -0.03409569 |
| Fifty Two Week Low | 144.26 |
| Fifty Two Week Low Change | 85.490005 |
| Fifty Two Week Low Change Percent | 0.5926106 |
| Fifty Two Week Range | 144.26 - 237.86 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 961,767,000,000 |
| Float Shares | 47,654,744 |
| Forward Eps | 12.32956 |
| Forward P E | 18.634079 |
| Free Cashflow | 510,023,744 |
| Full Exchange Name | NYSE |
| Full Time Employees | 18,300 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.34457 |
| Gross Profits | 1,387,579,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00636 |
| Held Percent Institutions | 1.23365 |
| Implied Shares Outstanding | 48,167,730 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ir Website | http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,766,793,600 |
| Long Business Summary | Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts. |
| Long Name | Charles River Laboratories International, Inc. |
| Market | us_market |
| Market Cap | 11,066,535,936 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_91093 |
| Most Recent Quarter | 1,774,656,000 |
| Net Income To Common | -184,650,000 |
| Next Fiscal Year End | 1,798,329,600 |
| Non Diluted Market Cap | 11,066,535,967 |
| Number Of Analyst Opinions | 15 |
| Open | 233.4 |
| Operating Cashflow | 607,025,984 |
| Operating Margins | 0.15923999 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.12 |
| Phone | 781 222 6000 |
| Pre Market Change | 0.94999695 |
| Pre Market Change Percent | 0.4134916 |
| Pre Market Price | 230.7 |
| Pre Market Time | 1,784,033,157 |
| Previous Close | 233.41 |
| Price Eps Current Year | 20.690723 |
| Price Hint | 2 |
| Price To Book | 3.7633088 |
| Price To Sales Trailing12 Months | 2.7480543 |
| Profit Margins | -0.04585 |
| Quick Ratio | 0.816 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.70588 |
| Region | US |
| Regular Market Change | -3.66 |
| Regular Market Change Percent | -1.56806 |
| Regular Market Day High | 235.81 |
| Regular Market Day Low | 224.57 |
| Regular Market Day Range | 224.57 - 235.81 |
| Regular Market Open | 233.4 |
| Regular Market Previous Close | 233.41 |
| Regular Market Price | 229.75 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 672,593 |
| Return On Assets | 0.04264 |
| Return On Equity | -0.0587 |
| Revenue Growth | 0.012 |
| Revenue Per Share | 81.963 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 48,167,730 |
| Shares Percent Shares Out | 0.0904 |
| Shares Short | 4,354,792 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,897,904 |
| Short Name | Charles River Laboratories Inte |
| Short Percent Of Float | 0.1043 |
| Short Ratio | 5.13 |
| Source Interval | 15 |
| State | MA |
| Symbol | CRL |
| Target High Price | 265.0 |
| Target Low Price | 135.0 |
| Target Mean Price | 230.93333 |
| Target Median Price | 235.0 |
| Total Cash | 191,830,000 |
| Total Cash Per Share | 3.983 |
| Total Debt | 3,064,531,968 |
| Total Revenue | 4,027,044,096 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.65 |
| Trailing Peg Ratio | 0.1222 |
| Triggerable | 1 |
| Two Hundred Day Average | 182.7372 |
| Two Hundred Day Average Change | 47.012802 |
| Two Hundred Day Average Change Percent | 0.25727 |
| Type Disp | Equity |
| Volume | 672,593 |
| Website | https://www.criver.com |
| Zip | 1,887 |